Evidence map›Paper›PMID 35189965›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2022

Activated phosphoinositide 3-kinase δ syndrome associated with nephromegaly, growth hormone deficiency, bronchiectasis: a case report.

Megan Craig, Bob Geng, Kristen Wigby, Susan A Phillips, Christine Bakhoum, John Naheedy, Mateja Cernelc-Kohan

Open access · goldAbstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Megan CraigUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA. mmcraig@health.ucsd.edu.ORCID http://orcid.org/0000-0002-6384-9138
Bob GengUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Kristen WigbyUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Susan A PhillipsUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Christine BakhoumSection of Pediatric Nephrology, Department of Pediatrics, Yale University, 333 Cedar Street, New Haven, CT, 06520, USA.
John NaheedyUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Mateja Cernelc-KohanUniversity of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
University of California San Diego · USChildren’s Institute · USYale University · US

Funding

Investigating the Significance of Nocturnal Blood Pressure Patterns in Children with Chronic Kidney DiseaseK23DK129836 · NIDDK · YALE UNIVERSITY · PI BAKHOUM, CHRISTINE · 2021 to 2025
$956k
American Heart Association 857722NIDDK NIH HHS K23 DK129836
6 · The paper itself

Abstract

backgroundActivated phosphoinositide 3-kinase (PI3K) δ syndrome (APDS) is a rare form of primary immunodeficiency with 243 known cases reported in the literature. Known findings associated with the condition include recurrent sinusitis and bronchitis, bronchiectasis, immune cytopenias, mild developmental delay, splenomegaly, and lymphadenopathy. We report the case of a child with APDS accompanied by unique clinical features: nephromegaly and growth hormone deficiency with associated pituitary anatomic abnormality. CASE PRESENTATION: The patient is a nine-year-old boy with a heterozygous de novo variant in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit δ (p.E1021K), previously reported in association with APDS. Our patient, who had no family history of immunodeficiency, exhibits classic findings of this syndrome but also has unique features that extend the phenotypic spectrum of this disorder. At 5 years of age, the patient showed marked growth deceleration and was demonstrated to have growth hormone (GH) deficiency with associated pituitary anatomic abnormality. He started GH therapy with an excellent response. He additionally has bilateral nephromegaly of unclear etiology, microscopic hematuria and proteinuria, asthma, and has developed left hip pain with arthrocentesis consistent with oligoarticular juvenile idiopathic arthritis. At age nine, the patient was referred to genetics and whole exome sequencing revealed APDS. Though there was initial concern that GH may increase risk for malignancy as GH signals through the PI3K pathway, he was allowed to continue treatment as the PI3K pathway was considered constitutively active at baseline.

conclusionsOur patient's unique presentation adds to the clinical information regarding APDS, demonstrates the utility of genetic testing and illustrates the importance of a multidisciplinary collaborative approach in managing this complex syndrome.

Indexed as

AsthmaBronchiectasisGrowth hormone deficiencyNephromegalyPituitary abnormalityPrimary immunodeficiency

Identifiers

PMID35189965
PMCPMC8862239
OpenAlexW4213263939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.